Trovafloxacin-induced weakness due to a demyelinating polyneuropathy.
Fluoroquinolones have been associated with peripheral sensory disorders and weakness, especially in patients with underlying myasthenia gravis or myasthenia-like Eaton-Lambert syndrome. Trovafloxacin is a relatively new quinolone for which these side effects have not been described. We report a case of diffuse weakness due to a demyelinating polyneuropathy that began after initiation of trovafloxacin in a patient without an underlying neurologic disorder.
Murray
C K
CK
Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.
Wortmann
G W
GW
D000890:Anti-Infective Agents / Q000009:adverse effects*; D003711:Demyelinating Diseases / Q000139:chemically induced*; D004576:Electromyography / Q000187:drug effects; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006801:Humans; D007866:Leg / Q000294:innervation; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000139:chemically induced*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation; D009287:Naphthyridines / Q000009:adverse effects*; D009431:Neural Conduction / Q000187:drug effects; D011115:Polyneuropathies / Q000139:chemically induced*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C080163:trovafloxacin